253 related articles for article (PubMed ID: 37718933)
1. A prospective study on the prevalence of MASLD in people with type-2 diabetes in the community. Cost effectiveness of screening strategies.
Forlano R; Stanic T; Jayawardana S; Mullish BH; Yee M; Mossialos E; Goldin R; Petta S; Tsochatzis E; Thursz M; Manousou P
Liver Int; 2024 Jan; 44(1):61-71. PubMed ID: 37718933
[TBL] [Abstract][Full Text] [Related]
2. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease.
Kjaergaard M; Lindvig KP; Thorhauge KH; Andersen P; Hansen JK; Kastrup N; Jensen JM; Hansen CD; Johansen S; Israelsen M; Torp N; Trelle MB; Shan S; Detlefsen S; Antonsen S; Andersen JE; Graupera I; Ginés P; Thiele M; Krag A
J Hepatol; 2023 Aug; 79(2):277-286. PubMed ID: 37088311
[TBL] [Abstract][Full Text] [Related]
3. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia.
Serra-Burriel M; Graupera I; Torán P; Thiele M; Roulot D; Wai-Sun Wong V; Neil Guha I; Fabrellas N; Arslanow A; Expósito C; Hernández R; Lai-Hung Wong G; Harman D; Darwish Murad S; Krag A; Pera G; Angeli P; Galle P; Aithal GP; Caballeria L; Castera L; Ginès P; Lammert F;
J Hepatol; 2019 Dec; 71(6):1141-1151. PubMed ID: 31470067
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis.
Asphaug L; Thiele M; Krag A; Melberg HO
Hepatology; 2020 Jun; 71(6):2093-2104. PubMed ID: 31595545
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of nonalcoholic steatohepatitis screening.
Zhang E; Wartelle-Bladou C; Lepanto L; Lachaine J; Cloutier G; Tang A
Eur Radiol; 2015 Nov; 25(11):3282-94. PubMed ID: 25994191
[TBL] [Abstract][Full Text] [Related]
6. Embedding assessment of liver fibrosis into routine diabetic review in primary care.
Mansour D; Grapes A; Herscovitz M; Cassidy P; Vernazza J; Broad A; Anstee QM; McPherson S
JHEP Rep; 2021 Aug; 3(4):100293. PubMed ID: 34179738
[TBL] [Abstract][Full Text] [Related]
7. Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.
Ajmera V; Tesfai K; Sandoval E; Lopez S; Cervantes V; Madamba E; Bettencourt R; Manousou P; Richards L; Loomba R
Hepatology; 2024 May; 79(5):1098-1106. PubMed ID: 37862551
[TBL] [Abstract][Full Text] [Related]
8. Stratification Of LIver Disease (SOLID): protocol for a prospective observational cohort study to determine the optimum biomarker strategies for the detection of advanced liver disease at the primary-secondary care interface.
McPherson S; Jarvis H; McGonigle J; Bedlington J; Dean J; Hallsworth K; Hanon E; Liddle T; Luvai A; Mansour D; Patel P; Renwick L; Teare D; Tanney C; Anstee Q
BMJ Open Gastroenterol; 2023 Feb; 10(1):. PubMed ID: 36754448
[TBL] [Abstract][Full Text] [Related]
9. Non-alcoholic fatty liver disease (NAFLD) and significant hepatic fibrosis defined by non-invasive assessment in patients with type 2 diabetes.
Sobhonslidsuk A; Pulsombat A; Kaewdoung P; Petraksa S
Asian Pac J Cancer Prev; 2015; 16(5):1789-94. PubMed ID: 25773826
[TBL] [Abstract][Full Text] [Related]
10. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.
Ajmera V; Cepin S; Tesfai K; Hofflich H; Cadman K; Lopez S; Madamba E; Bettencourt R; Richards L; Behling C; Sirlin CB; Loomba R
J Hepatol; 2023 Mar; 78(3):471-478. PubMed ID: 36410554
[TBL] [Abstract][Full Text] [Related]
11. Modelling the cost effectiveness of non-alcoholic fatty liver disease risk stratification strategies in the community setting.
Congly SE; Shaheen AA; Swain MG
PLoS One; 2021; 16(5):e0251741. PubMed ID: 34019560
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: A cost-effectiveness and price threshold analysis.
Choo BP; Goh GBB; Chia SY; Oh HC; Tan NC; Tan JYL; Ang TL; Bee YM; Wong YJ
Ann Acad Med Singap; 2022 Nov; 51(11):686-694. PubMed ID: 36453216
[TBL] [Abstract][Full Text] [Related]
13. Performance of the Enhanced Liver Fibrosis Test to Estimate Advanced Fibrosis Among Patients With Nonalcoholic Fatty Liver Disease.
Younossi ZM; Felix S; Jeffers T; Younossi E; Nader F; Pham H; Afendy A; Cable R; Racila A; Younoszai Z; Lam BP; Golabi P; Henry L; Stepanova M
JAMA Netw Open; 2021 Sep; 4(9):e2123923. PubMed ID: 34529067
[TBL] [Abstract][Full Text] [Related]
14. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study.
Tanajewski L; Harris R; Harman DJ; Aithal GP; Card TR; Gkountouras G; Berdunov V; Guha IN; Elliott RA
BMJ Open; 2017 Jul; 7(6):e015659. PubMed ID: 28679676
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of steatotic liver disease, MASLD, MetALD and significant fibrosis in people with HIV in the United States.
Gawrieh S; Vilar-Gomez E; Woreta TA; Lake JE; Wilson LA; Price JC; Naggie S; Sterling RK; Heath S; Corey KE; Cachay ER; Ajmera V; Tonascia J; Sulkowski MS; Chalasani N; Loomba R
Aliment Pharmacol Ther; 2024 Mar; 59(5):666-679. PubMed ID: 38158589
[TBL] [Abstract][Full Text] [Related]
17. Effect of Concurrent Metabolic Dysfunction-Associated Steatotic Liver Disease on Serial Non-invasive Fibrosis Markers in Chronic Hepatitis B.
Con D; Tu S; Clayton-Chubb D; Lubel JS; Nicoll AJ; Sawhney R; Bloom S
Dig Dis Sci; 2024 Apr; 69(4):1496-1506. PubMed ID: 38376788
[TBL] [Abstract][Full Text] [Related]
18. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE.
Doycheva I; Cui J; Nguyen P; Costa EA; Hooker J; Hofflich H; Bettencourt R; Brouha S; Sirlin CB; Loomba R
Aliment Pharmacol Ther; 2016 Jan; 43(1):83-95. PubMed ID: 26369383
[TBL] [Abstract][Full Text] [Related]
19. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
[TBL] [Abstract][Full Text] [Related]
20. Transient elastography for the prevalence of non-alcoholic fatty liver disease in patients with type 2 diabetes: Evidence from the CORDIAL cohort study.
Alfadda AA; Sherbeeni SM; Alqutub AN; Aldosary AS; Aldaghri NM; Taylor-Robinson SD; Alqahtani SA; Gul R; Almaghamsi AM
Saudi J Gastroenterol; 2022; 28(6):426-433. PubMed ID: 35645140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
